Design, synthesis and biological evaluation of a novel class of indazole-containing compounds with potent anti-influenza activities targeting the PA-PB1 interface.
10.1016/j.apsb.2025.04.014
- Author:
Yun-Sang TANG
1
;
Chao ZHANG
2
;
Jing XU
2
;
Haibo ZHANG
2
;
Zhe JIN
2
;
Mengjie XIAO
1
;
Nuermila YILIYAER
1
;
Er-Fang HUANG
2
;
Xin ZHAO
3
;
Chun HU
2
;
Pang-Chui SHAW
1
Author Information
1. School of Life Sciences and Centre for Protein Science and Crystallography, Faculty of Science, The Chinese University of Hong Kong, Hong Kong SAR, China.
2. Key Laboratory of Structure-based Drug Design & Discovery (Ministry of Education), Shenyang Pharmaceutical University, Shenyang 110016, China.
3. Guangdong Provincial Key Laboratory of Chemical Measurement and Emergency Test Technology, Institute of Analysis, Guangdong Academy of Sciences, China National Analytical Center, Guangzhou 510070, China.
- Publication Type:Journal Article
- Keywords:
Anti-influenza compounds;
Compound library synthesis;
Indazole-containing compounds;
Influenza;
Lead discovery and optimization;
PA-PB1 inhibitors;
Pharmacodynamics study;
Polymerase inhibitors
- From:
Acta Pharmaceutica Sinica B
2025;15(6):3163-3180
- CountryChina
- Language:English
-
Abstract:
The PA-PB1 interface of the influenza polymerase is an attractive site for antiviral drug design. In this study, we designed and synthesized a mini-library of indazole-containing compounds based on rational structure-based design to target the PB1-binding interface on PA. Biological evaluation of these compounds through a viral yield reduction assay revealed that compounds 27 and 31 both had a low micromolar range of the half maximal effective concentration (EC50) values against A/WSN/33 (H1N1) (8.03 μmol/L for 27; 14.6 μmol/L for 31), while the most potent candidate 24 had an EC50 value of 690 nM. Compound 24 was effective against different influenza strains including a pandemic H1N1 strain and an influenza B strain. Mechanistic studies confirmed that compound 24 bound PA with a K d which equals to 1.88 μmol/L and disrupted the binding of PB1 to PA. The compound also decreased the lung viral titre in mice. In summary, we have identified a potent anti-influenza candidate with potency comparable to existing drugs and is effective against different viral strains. The therapeutic options for influenza infection have been limited by the occurrence of antiviral resistance, owing to the high mutation rate of viral proteins targeted by available drugs. To alleviate the public health burden of this issue, novel anti-influenza drugs are desired. In this study, we present our discovery of a novel class of indazole-containing compounds which exhibited favourable potency against both influenza A and B viruses. The EC50 of the most potent compounds were within low micromolar to nanomolar concentrations. Furthermore, we show that the mouse lung viral titre decreased due to treatment with compound 24. Thus our findings identify promising candidates for further development of anti-influenza drugs suitable for clinical use.
